STTCOMP PAA, FA Long Pharmaust SP:$0.06 MC:$12 mill Cash: $2m...

STTCOMP PAA, FA Long

Pharmaust

SP:$0.06
MC:$12 mill
Cash: $2m Post raise and Tax Refund


PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues.



PAA’s lead candidate is Monepantel (MPL), a small molecule drug currently being developed as a novel, safe and potent treatment for cancer. One of monepantel’s key clinical attributes is its low toxicity as evidenced by its approved use in food chain animals and by PharmAust’s own Phase I trial.
PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumours. All trials achieved their primary clinical endpoints in terms of safety and reduction in key clinical biomarkers. The company has also initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma.
PharmAust has also initiated a preclinical programme to screen its portfolio of proprietary aminoacetonitrile (AAD) compounds for anticancer activity. These novel compounds are related to but distinct from monepantel and have the potential to provide the company with a fully-proprietary oncology pipeline.



News today of Pharmaust teaming up with the Olivia Newton-John Cancer Research centre "to better understand how Pharmaust's leading clinical candidate, monepantel (MPL) is able to kill cancer cells" should bring some increased awareness to this very cheap but exciting ASX Oncology play trading at a fraction of its peers